alloantibody
sotrovimab
monospecific
glembatumumab
intetumumab
indatuximab ravtansine
brentuximab
tocilizumab
sarilumab
afutuzumab
autoepitope
toripalimab
vanucizumab
ziltivekimab
lorvotuzumab
pozelimab
immunocarrier
amlitelimab
heteroclitic
zenocutuzumab
sintilimab
dinutuximab
cergutuzumab
solitomab
sasanlimab
retifanlimab
tigatuzumab
zanolimumab
pancytokeratin
immunopanning
robatumumab
siltuximab
antiustekinumab
idiospecific
antitoxin
immunocharacterize
leronlimab
antigenomic
caplacizumab
olendalizumab
agonistic monoclonal antibody
hyperimmunized
complement
affitin
teneliximab
inotuzumab
patritumab
immunoprinting
conatumumab
duligotuzumab